echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sansheng Guojian SSGJ-706 injection obtained the "Notice of Drug Clinical Trial Approval"

    Sansheng Guojian SSGJ-706 injection obtained the "Notice of Drug Clinical Trial Approval"

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 27th, Sansheng Guojian issued an announcement stating that the company received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Food and Drug Administration, approving the company's bispecific antibody injection SSGJ-706 to develop in advanced solid tumors and recurrences.


    The current anti-PD1 monoclonal antibody/anti-PDL1 monoclonal antibody single agent and combination chemotherapy have shown superior efficacy than previous standard treatments in many tumor fields


    SSGJ-706 is a recombinant bispecific antibody developed by Sansheng Guojian using the bispecific antibody platform with independent intellectual property rights.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.